Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite for Free

New feature: Introducing the Finviz Matrix

BeyondSpring, Inc.

Contributing Author

Recent Articles by BeyondSpring, Inc.

Aug-14	BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update BYSI -15.78% BYSI -15.21% GlobeNewswire
Jun-04	BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value BYSI GlobeNewswire
Jun-02	BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 BYSI GlobeNewswire
May-18	BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting BYSI GlobeNewswire
May-13	BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update BYSI GlobeNewswire
Apr-22	BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs BYSI -6.32% GlobeNewswire
Mar-30	BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 BYSI GlobeNewswire
Mar-25	BeyondSpring Files 2025 Annual Report on Form 10-K BYSI GlobeNewswire
Mar-25	BeyondSpring Reports 2025 Year-End Financial Results BYSI GlobeNewswire
Feb-09	BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360 Conference BYSI GlobeNewswire
Dec-12	BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path BYSI GlobeNewswire
Dec-11	BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 BYSI +7.92% GlobeNewswire
Nov-12	BeyondSpring Reports Third-Quarter 2025 Financial Results and Provides Corporate Update BYSI GlobeNewswire
Aug-13	BeyondSpring Reports Second-Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment BYSI GlobeNewswire
Jul-07	BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure BYSI GlobeNewswire
Jun-03	BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting BYSI GlobeNewswire
May-28	BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting BYSI -5.68% GlobeNewswire
May-12	BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update BYSI GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)